Semax FDA status is easy to misread. Semax has never had an FDA-approved U.S. product. On July 24, 2026, an FDA advisory committee recommended putting two Semax ingredients on a federal compounding list. That was a recommendation, not drug approval and not a list change.
The distinction matters. The committee was answering whether Semax free base and Semax acetate should be eligible ingredients for certain patient-specific compounded prescriptions. It was not deciding whether Semax is safe and effective as an approved medicine. If you want the biology rather than the regulatory story, our guide to how Semax works keeps those questions separate.
The Semax FDA history starts with two nominations
The public record begins with nominations from Wells Pharmacy Network and LDT Health Solutions. FDA identifies them as document FDA-2015-N-3534-0284 in its 2015 docket and FDA-2018-N-2973-0002 in its 2018 docket. Those submissions asked FDA to consider Semax for the 503A Bulks List.
The 503A Bulks List is a federal list of ingredients that traditional compounding pharmacies may use when the other ingredient pathways in the law do not apply. A bulk drug substance is simply the active ingredient used to prepare a medication. Being nominated starts a review; it does not put the ingredient on the list.
There was an identity problem from the beginning. In its May 11, 2026 staff briefing, FDA said the nomination packages were inconsistent about whether they meant Semax free base or Semax acetate. The agency therefore evaluated both. It considered cerebral ischemia, migraine, and trigeminal neuralgia; our separate page on what Semax is used for covers the broader use question without treating those uses as approvals.
Why FDA placed Semax in Category 2 in 2023
In an update dated September 29, 2023, FDA moved Semax into Category 2, its interim group for nominated substances that raise significant safety concerns. Category 2 was a working policy category, not a final ruling on the 503A list.
The agency’s current safety summary preserves the reasoning. FDA pointed to possible immunogenicity, meaning an unwanted immune response, from aggregation and peptide-related impurities. It also said safety information for the proposed routes was absent or limited. That explains the category; it does not turn the category into a drug-approval decision.
The nominations were withdrawn in April 2026
On April 22, 2026, FDA removed Semax from Category 2 because the nominators had withdrawn their submissions. The withdrawal records are FDA-2015-N-3534-0484 and -0485. FDA did not stop there: it continued evaluating the two Semax forms on its own initiative and scheduled an advisory meeting.
The current FDA categories PDF is stamped “Updated May 14, 2026.” Semax no longer appears in Category 2. FDA’s linked safety page instead places it under “bulk drug substances nominated but withdrawn.” That move did not put Semax in Category 1 or on the 503A Bulks List.
The Semax FDA review in 2026 recommended against listing
FDA staff’s May briefing weighed against placing either Semax form on the list. The agency found no applicable USP or National Formulary monograph, and no drug already approved in the United States contains either ingredient. It also found gaps in chemical characterization, impurities, aggregation testing, and safety evidence.
One sentence in the review does a lot of work: FDA reported finding no human pharmacokinetic study by any route. Pharmacokinetics describes how the body absorbs, moves, and clears a substance. A 2006 tracking study followed intranasal Semax in rats, not people. A 2018 study scanned 24 healthy volunteers before and shortly after intranasal Semax or placebo, but it measured brain-network imaging rather than blood levels, clearance, or a clinical outcome. Neither paper fills the human pharmacokinetic gap.
Staff also judged the evidence insufficient for cerebral ischemia, migraine, or trigeminal neuralgia. This was a review of the evidence submitted and found for those nominated uses—not a review of every claim made about Semax online.
The Semax PCAC vote went the other way
The Pharmacy Compounding Advisory Committee, or PCAC, is an outside expert panel that advises FDA. Semax came up during the afternoon session on July 24, the second day of the July 23–24 meeting. The official agenda names FDA presenters Marianne San Antonio, DO, Jing Li, PhD, and Jamiele Mattocks, PharmD.
After the public hearing and FDA presentation, the committee voted 8–5, with one abstention, to recommend inclusion of both Semax free base and Semax acetate. In plain language, the panel disagreed with staff’s recommendation. The FDA meeting page holds the agenda, briefing materials, questions, roster, presentations, and official recording.
That vote is the fresh development. It is also where the story is most often overstated. Advisory committees give FDA advice; FDA makes the regulatory decision. An 8–5–1 recommendation did not approve a Semax product, add an ingredient to the list, or erase the concerns in the staff review.
What happened after the Semax PCAC vote
As of September 9, 2026, the day this article was written, the FDA’s current categories document still shows Semax outside Categories 1, 2, and 3, while its safety page lists Semax among nominations that were withdrawn. A search of the Federal Register found no proposed or final rule adding Semax to the 503A Bulks List. The only Semax-specific 2026 entry was the April 16 meeting notice.
The next formal step would be notice-and-comment rulemaking: FDA would publish proposed regulatory text, accept public comments, and then decide whether to issue a final rule. Until that happens, the July vote remains a recommendation.
What this does and does not change for a patient
Regulatory review status is never a marketing gate. It should be described honestly, then handled as one part of a clinical conversation. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. Federal and state compounding rules and pharmacy availability still apply.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The live Promise option is the Semax / Selank blend, not standalone Semax. Single-agent Semax is a waitlist product and is not promoted here. If you are sorting out the names, Semax versus Selank explains the difference without changing the regulatory facts above.
A compounded preparation is different from an approved medicine. It is made for an individual prescription and is not an FDA-approved product. The careful takeaway is narrow: the committee vote moved the discussion forward, but it did not finish the process.